This site and its domain are for sale. Email the owner if you want to talk about it.

bariatricalt.com

Surgery, Endoscopy or Medication: The Side-by-Side Chart

Sleeve, bypass, endoscopic sleeve, balloon and GLP-1 medication compared on the published evidence: average weight loss, diabetes remission, durability, typical cost and who each suits best, on one printable chart.

This is a chart of five ways to lose a large share of body weight, set side by side on the things published studies actually measured. Two options have a surgeon remove or reroute part of the stomach: the sleeve and the bypass. One has a gastroenterologist stitch the stomach smaller from the inside: the endoscopic sleeve. One is a balloon. One is a drug: semaglutide or tirzepatide, the GLP-1 medications. Each cell holds a number, the study it came from, and enough context to know how much weight the number can bear.

The rule for reading it is that the units are not interchangeable. Total weight loss is the share of starting body weight that came off. Excess weight loss is the share of the weight above a reference point that came off. The MERIT trial, for example, defined that reference point as a BMI of 25. Excess weight loss is a fraction of a smaller number, so it always looks bigger. A table that mixes the two without labels will flatter whichever option happened to report the bigger-looking unit.

What is not settled is a fairly long list. There are no five-year numbers yet for the endoscopic sleeve or the balloon, and no long-term drug data that rival the 10-year surgical trials. None of these sources gives a typical price for any option. Most drug figures and most surgery figures come from different studies of different people, which reviewers then line up next to each other. The chart does the same thing, and says so.

Weight lost after one and five years

OptionWeight lost after one yearWeight lost after five years
Gastric bypassNot settled for bypass alone in these sources22.2 percent in the Oseberg randomized trial; 28.1 percent in a five-year cohort of patients with preoperative dysglycemia
Gastric sleeveNot settled for sleeve alone in these sources17.2 percent in Oseberg; 24.0 percent in the dysglycemia cohort; 27.4 percent in the standard arm of a banded versus non-banded sleeve trial; 25 to 30 percent at 2 to 5 years in a review
Endoscopic sleeve13.6 percent at 52 weeks in the MERIT trial, versus 0.8 percent for controls; 13 to 16 percent at 12 months in a reviewNot settled; a review reports results sustained up to 3 years
Gastric balloonAbout 10 to 15 percent in a 2023 to 2025 narrative reviewNot settled; the loss is not sustained after removal
GLP-1 drugsAbout 10 to 15 percent for GLP-1 agonists in the same review; 22.5 percent for tirzepatide 15 mg in SURMOUNT-114.9 to 20.9 percent for semaglutide or tirzepatide in a 2026 systematic review, against 25 to 32 percent sustained five-year loss for surgery

Ten years and beyond

OptionHorizon and studyResult
Gastric bypass10 years, SLEEVEPASS randomized trial, 85 percent follow-up51.9 percent excess weight loss, versus 43.5 percent for sleeve
Gastric bypass10 to 20 years, Geisinger single centerTotal weight loss stabilized at 23 percent
Gastric bypass7 years, LABS study28.4 percent of baseline weight, or 38.2 kg
Gastric sleeve10 years, weighted mean across studies24.4 percent total weight loss
One anastomosis bypass10 years64.1 percent excess weight loss
Duodenal switch10 yearsAbout 40 percent total weight loss; 76.5 to 78 percent excess BMI loss, with significant nutritional concerns
Adjustable band7 years, LABS study14.9 percent of baseline weight, or 18.8 kg
Endoscopic sleeveNot settledNot settled
Gastric balloonNot settledNot settled
GLP-1 drugsNot settledNot settled

Diabetes remission

OptionFindingStudy
Gastric bypass63 percent at 5 years with HbA1c below 6.5 percent; 50 percent with the stricter cutoff of 6.0 percentOseberg randomized trial
Gastric sleeve30 percent at 5 years with HbA1c below 6.5 percent; 20 percent with the 6.0 percent cutoffOseberg randomized trial
Bypass versus sleeve, earlier67 versus 33 percent at 3 years; at 1 year a risk difference of 27 percentage points favoring bypassOseberg randomized trial
Gastric bypass53.3 percent, 8 of 15, at 10 yearsDIABETCIR trial
Gastric sleeve25 percent, 3 of 12, at 10 yearsDIABETCIR trial
Greater curvature plication26.7 percent, 4 of 15, at 10 yearsDIABETCIR trial
Bypass after weight regain75 percent kept remission at 5 years despite regain, versus 34.8 percent after sleeve; odds of recurrence 5.5 times higher after sleeveMayo Clinic study
Bypass after regaining all lost weightAbout 60 percent still in remissionWeight recurrence study
One anastomosis bypass, 5 years or more80 percent type 2 diabetes resolution across 32 studies and 19,125 patientsMeta-analysis
Endoscopic sleeve60 percent remission with mild, 45.5 percent with moderate and 0 percent with severe diabetes on the IMS scoreIMS score study
Gastric balloonNot settledNone in these sources
GLP-1 drugs5.8 percent by strict off-medication criteria, up to 18.3 percent by inclusive definitions, among 14,141 initiators followed a mean of 4 yearsObservational study

Who keeps remission after surgery

FactorFindingStudy
Relapse rate882 patients, 42.9 percent, restarted diabetes medication after at least 90 medication-free daysMedication re-initiation study
TimingMedian time to restarting was 1.04 yearsMedication re-initiation study
ProcedureBypass carried lower risk of restarting than sleeve, hazard ratio 0.778Medication re-initiation study
Diabetes durationLonger duration raised the risk, hazard ratio 1.219 per standard deviation; shorter duration predicted lasting remission in DIABETCIRRe-initiation study; DIABETCIR
Insulin before surgeryHazard ratio 1.627Medication re-initiation study
Baseline HbA1cHigher HbA1c raised the risk, hazard ratio 1.089 per standard deviationMedication re-initiation study
AgeNot independently associatedMedication re-initiation study
First yearGreater first-year weight loss and early rises in GLP-1 secretion predicted lasting remission regardless of techniqueDIABETCIR trial

Durability and regain

OptionFindingStudy
Gastric bypassMean regain of 3.9 percent of baseline weight between years 3 and 7LABS study
Gastric bypassWeight regain affects 10 to 30 percent of patientsPouch resizing study
Gastric bypassAdvantages over sleeve at 1 and 5 years were attenuated at 10 yearsDIABETCIR trial
Gastric sleeveUp to half of patients may need conversion surgerySeven-year conversion study
Endoscopic sleeve68 percent kept at least 25 percent excess weight loss at 104 weeksMERIT trial
Gastric balloonLoss is not sustained after device removalEndobariatrics review
GLP-1 drugsPeople who stopped were 17.90 percentage points behind those who continuedDiscontinuation meta-analysis
GLP-1 drugsAfter stopping tirzepatide, 9 to 12 percent of body weight returned within 6 months, with about half the net loss retainedSURMOUNT-CN extension

Cost and who each option suits best

OptionTypical costWhere the evidence is strongest
Gastric bypassNot publicType 2 diabetes, where it beat sleeve on remission at 1, 3 and 5 years in Oseberg; also weight-related quality of life, 9.4 points better than sleeve at 3 years
Gastric sleeveNot publicWeight loss of 25 to 30 percent at 2 to 5 years; a network meta-analysis put it at 21.1 percent, statistically level with tirzepatide 10 or 15 mg at 21.3 percent
Endoscopic sleeveNot publicClass 1 and 2 obesity, the MERIT trial population; ranked highest for weight loss among endoscopic therapies at 12 months, ahead of the Spatz3 and Orbera balloons
Gastric balloonNot publicShort-term loss; at removal, all FDA-approved endoscopic therapies beat control
GLP-1 drugsNot publicTrial populations such as SURMOUNT-CN, 210 adults with mean BMI 32.3; remission is likelier with shorter diabetes duration, lower HbA1c, lighter treatment burden and preserved beta-cell function

After a sleeve that underperformed

RouteFindingStudy
Conversion to bypass versus adding a GLP-1 drug26.1 versus 13.7 percent total weight loss at 3 years, among 4,901 patientsMulticenter retrospective study
SADI versus one anastomosis bypassSADI produced greater weight loss at 1 yearRevisional meta-analysis
One anastomosis bypass as revisionDiabetes remission of 65.16 percent at 1 year, 65.37 percent at 3 years and 78.10 percent at 5 yearsRevisional meta-analysis
Pouch resizing after bypassBMI from 39 to 35 at 5 years; comorbidities resolved in 53 percent; 10.4 percent serious complicationsHigh-volume single center
Liraglutide plus endoscopic therapyComparable to net loss after surgery aloneSystematic review

How to read this

Read across a row for one study and down a column with caution. The Oseberg trial gives the cleanest bypass versus sleeve comparison because it randomized patients, and its numbers run lower than some cohorts. The 2026 systematic review found surgery ahead of incretin drugs on all five of its primary domains: diabetes remission, weight, major cardiac events and death, NASH resolution, and quality of life. Remission also depends on the cutoff. The same Oseberg patients show 63 percent or 50 percent remission depending on whether the HbA1c line sits at 6.5 or 6.0. Definitions of failure vary too. One review defines weight recurrence as a rise of 25 percent of excess weight loss from the lowest weight. BARI-STEP defined a poor response as under 20 percent loss.

What would change it

The biggest missing cells would fill in with longer endoscopic sleeve follow-up beyond MERIT’s 104 weeks and with randomized drug data running five years and more. The BYPSADIS trial, which compares SADI-S with bypass, will report the share of patients above 30 percent total weight loss at 5 years. Published prices would replace a column that currently says not public. A randomized trial of surgery against tirzepatide or semaglutide in the same patients would settle what the reviews can only approximate.

Sources

  1. Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
  2. Laparoscopic Single Anastomosis Duodeno-Ileal Bypass Versus One Anastomosis Gastric Bypass as Revisional Procedures after Sleeve Gastrectomy: Meta-analysis and Systematic Review
  3. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.
  4. Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study
  5. A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
  6. Diabetes remission 10 years after bariatric surgery: Extension study of a randomized controlled trial
  7. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial
  8. Gastric Bypass Improves Long-Term Diabetes Remission, Even After Weight Recurrence | ACS
  9. Continued Diabetes Remission Despite Weight Recurrence: Gastric Bypass Long-Term Metabolic Benefit.
  10. Shaping the Future of Restrictive Bariatric Surgery: Clinical, Economic, and Long-Term Perspectives on Endoscopic and Laparoscopic Sleeve
  11. Baseline Diabetes Severity Is the Dominant Predictor of Diabetes Medication Re-Initiation Following Bariatric Surgery
  12. Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study
  13. Seven-Year Comparative Outcomes of One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass for Weight Recurrence Regain Post Sleeve Gastrectomy
  14. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial
  15. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
  16. Pouch Resizing for Weight Regain after Roux-En-Y Gastric Bypass: Results from a High-Volume Single Center
  17. Banded Versus Non-banded Sleeve Gastrectomy: 5-Year Results of a 3-Year Randomized Controlled Trial
  18. Roux-en-Y gastric bypass results in long-term durable weight loss and diabetes remission: a single center, > 15 year outcomes
  19. New Study Shows Long-term Effectiveness of Gastric Bypass in Treating Type 2 Diabetes and Obesity - American Society for Metabolic and Bariatric Surgery
  20. Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
  21. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
  22. A randomized open-label multicentre clinical trial comparing single-anastomosis duodenal switch (SADI-S) versus Roux-en-Y gastric bypass for the treatment of severe obesity: BYPSADIS study protocol
  23. Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study
  24. Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review
  25. Comparative effectiveness of balloons, adjustable balloons, and endoscopic sleeve gastroplasty: a network meta-analysis of randomized trials
  26. Long-Term Outcomes of One Anastomosis Gastric Bypass: A Systematic Review and Meta-Analysis of 5-Year and Beyond
  27. GLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss
  28. One Anastomosis/Mini-Gastric Bypass (OAGB/MGB) as Revisional Surgery Following Primary Restrictive Bariatric Procedures: a Systematic Review and Meta-Analysis
  29. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
  30. Frontiers | Endoscopic Management of Weight Recurrence Following Bariatric Surgery
  31. Scholars@Duke publication: Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial.
  32. Endobariatrics: well past infancy and maturing rapidly
  33. Comparison of 5-year glycemic outcomes after sleeve gastrectomy and Roux-en-Y gastric bypass in patients with pre-operative dysglycemia
  34. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial
  35. Tirzepatide Once Weekly for the Treatment of Obesity
  36. Lilly's SURMOUNT-1 results published in The New ...
  37. Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis
  38. 1672-P: Weight Changes after Tirzepatide Cessation in Chinese Adults with Overweight/Obesity—A Real-World Follow-up Study of SURMOUNT-CN Trial
  39. Lifestyle Modification and Bariatric Surgery in Type 2 Diabetes Remission : Short title: Diabetes Remission Strategies in T2DM
  40. Advances in Metabolic Bariatric Surgeries and Endoscopic Therapies: A Comprehensive Narrative Review of Diabetes Remission Outcomes
  41. Applicability of individualized metabolic surgery score for prediction of diabetes remission after endoscopic sleeve gastroplasty

Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.